Answers are grounded in this paper and cite their sources.
Evaluates controlled delivery of AmB using Eudragit and silk fibroin nanoparticles, suggesting enhanced efficacy and reduced toxicity.
AIMS: Amphotericin B (AmB) is the first-line antifungal compound for severe fungal infections, yet it possesses high renal toxicity, low water solubility, and acidic instability in the stomach. Herein, we developed novel nanoparticles from silk fibroin with/without Eudragit E100 (FNP and FNP/EE) for the controlled oral delivery of AmB. METHODS AND RESULTS: antifungal activity. CONCLUSIONS: The particles solved the AmB limitations by (1) protecting AmB from the gastric environment, (2) controlling AmB release, (3) reducing AmB toxicity, and (4) preserving AmB efficacy.
No takes yet. Share an insight, caveat, or question.
Pham et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: